Coulie Bernard's Form 4 filing
Pliant Therapeutics, Inc. (PLRX) · filed Feb 1, 2023
- Accession no.
- 0001140361-23-003977
- Filed
- Feb 1, 2023
- Trade date
- Jan 30-Feb 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 10 non-derivative transactions and 4 derivative transactions. Open-market sales total $1.55M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Coulie BernardCIK 0001808895 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 30, 2023 | Common Stock | MOption exerciseAcquired | +15,000 | $2.08 | +$31,200 | 255,112 | Direct | |
| Jan 30, 2023 | Common Stock | SSaleDisposed | −11,395 | $33.98F2 | −$387,202.1 | 243,717 | Direct | |
| Jan 30, 2023 | Common Stock | SSaleDisposed | −3,605 | $34.66F3 | −$124,949.3 | 240,112 | Direct | |
| Jan 31, 2023 | Common Stock | MOption exerciseAcquired | +10,539 | $2.08 | +$21,921.12 | 250,651 | Direct | |
| Jan 31, 2023 | Common Stock | MOption exerciseAcquired | +4,461 | $6.22 | +$27,747.42 | 255,112 | Direct | |
| Jan 31, 2023 | Common Stock | SSaleDisposed | −15,000 | $34.92 | −$523,800 | 240,112 | Direct | |
| Feb 1, 2023 | Common Stock | MOption exerciseAcquired | +15,000 | $6.22 | +$93,300 | 255,112 | Direct | |
| Feb 1, 2023 | Common Stock | SSaleDisposed | −9,455 | $34.15F4 | −$322,888.25 | 245,657 | Direct | |
| Feb 1, 2023 | Common Stock | SSaleDisposed | −5,440 | $34.78F5 | −$189,203.2 | 240,217 | Direct | |
| Feb 1, 2023 | Common Stock | SSaleDisposed | −105 | $35.55F6 | −$3,732.75 | 240,112 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 30, 2023 | Common Stock | MOption exerciseDisposed | −15,000 | $0.00 | $0 | 157,380 | Direct | |
| Jan 31, 2023 | Common Stock | MOption exerciseDisposed | −10,539 | $0.00 | $0 | 146,841 | Direct | |
| Jan 31, 2023 | Common Stock | MOption exerciseDisposed | −4,461 | $0.00 | $0 | 372,262 | Direct | |
| Feb 1, 2023 | Common Stock | MOption exerciseDisposed | −15,000 | $0.00 | $0 | 357,262 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.56 to $34.55, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.56 to $34.92, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.52 to $34.50, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.52 to $35.42, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $35.65, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4.
Referenced by the price of 1 transaction in Table I.